|
Post by uvula on Mar 25, 2019 10:07:50 GMT -5
We dropped below $2 again and no one is posting anything here. So quiet. So very quiet.
|
|
|
Post by bill on Mar 25, 2019 10:12:19 GMT -5
We dropped below $2 again and no one is posting anything here. So quiet. So very quiet. uvula - We're just doing what MNKD management is doing at the moment--which is (visibly) not a lot...
|
|
|
Post by brotherm1 on Mar 25, 2019 10:58:15 GMT -5
Concerted shorting started last week by SA
|
|
|
Post by traderdennis on Mar 25, 2019 11:22:19 GMT -5
Concerted shorting started last week by SA Wall Street reacting that the 2.38 warrants are not going to get exercised is more like the news here.
|
|
|
Post by brotherm1 on Mar 25, 2019 12:19:29 GMT -5
Concerted
|
|
|
Post by brianrocco on Mar 25, 2019 15:28:50 GMT -5
I just reread the transcript of the 2/26 conference call in which MC anticipated that a UT milestone might be met by this quarter's end. That should give a boost to the per share price if achieved. I am guessing that MannKind has another ten days to achieve the milestone in order to effect exercise of the warrants. I wait quietly with fingers crossed.
|
|
|
Post by mytakeonit on Mar 25, 2019 16:28:52 GMT -5
Under $2 Yahooooo !!! Hey Martha ... it's another buying opportunity !!!
|
|
|
Post by falconquest on Mar 25, 2019 18:04:55 GMT -5
Under $2 Yahooooo !!! Hey Martha ... it's another buying opportunity !!! That's one thing that you can always count on with Mannkind..........another buying opportunity!
|
|
|
Post by sportsrancho on Mar 25, 2019 19:47:07 GMT -5
The stock is trading according to the trend line, we’re just about to hit the “golden cross” ..support I believe is $1.90. We should bounce now, or in a couple days, and head back up “stairs steps” 👍🏻
|
|
|
Post by sweedee79 on Mar 25, 2019 20:16:58 GMT -5
The stock is trading according to the trend line, we’re just about to hit the “golden cross” ..support I believe is $1.90. We should bounce now, or in a couple days, and head back up “stairs steps” 👍🏻 Thanks for this.. sure hope it's right.. I saw someone on ST say this about a week ago. Sure is a tough stock to be in.. and it's just been wierd the last few weeks like something is smoldering and just about to ignite. Doesn't seem to me like we are going down again.. not this time.. 🙏 .. hang in there everyone!!!!!
|
|
|
Post by mango on Mar 25, 2019 21:44:48 GMT -5
Maybe a Golden Cross will lead to a Golden Eternity
|
|
|
Post by bradleysbest on Mar 25, 2019 23:41:05 GMT -5
To answer the question...Just doing my David Kendall impersonation.
|
|
|
Post by akemp3000 on Mar 26, 2019 6:03:15 GMT -5
Nothing much going on lately. Just waiting on the next action. Hopefully sooner rather than later.
|
|
|
Post by prcgorman2 on Mar 26, 2019 6:12:16 GMT -5
uvula makes an interesting point which is the correlation between this board’s activity and activity in the marketplace. Many of us hang on the barest shreds of information; a Tweet, Facebook exchanges, a post from a respected member of our community, an amateur (or not) blog or hit piece written on some Internet rag such as Seeking Alpha or Motley Fool, and let’s not forget, the weekly (or is that weakly?) prescription counts.
Up until the flat-as-a-pancake Rx counts for the month of March, the general outlook had improved especially since the last quarter’s earnings report and the posting had become more buoyant. But the downward trend in the stock price (from “concerted” shorting?) at the end of last week capped by stalled TRx brought out the boo birds either real or incented as though something material had happened.
One of the things I’ve decided I like about the TV DTC is it makes Afrezza “legit”. I’m confident folks will pounce on that. :-)
The reason I assert this is we humans come to accept the things to which we have become accustomed, good or bad. The term used in advertising and marketing is mindshare. Afrezza is earning mindshare amongst prescribers, insurers, PWDs that were unaware of Afrezza (which is probably most of them), elected officials, regulators, distributors, pharmacists, investors. One can argue about the effectiveness but not the effect.
I came here as an idiot investing in “inhalable insulin” because of course who the Hell WANTS to use needles on themselves? It just has to be a very small group. It’s weird that it is a group at all, but I won’t go there.
I learned I didn’t know diddly squat about what I had invested in and that was very embarassing especially since I made a substantial investment, right after FDA approval. I couldn’t have timed it worse if I had tried, literally. And not being a saavy trader, I just accumulated more to at least try to benefit from dollar cost averaging, which is a great strategy that Sanofi contributed the most to. Then there was the 1:5 reverse split was also like a kick in the groin. And the very obvious dilution that was required that came afterward. Adam Fuerstein once called MNKD a “battleground stock”. I imagine something like the trench warfare in WWI with constant bombardment and the wide ranging battles causing a lot of civilians casualties too.
Being here I also learned a lot about Afrezza and diabetes and from haunting Tudiabetes and reading DiabetesMine and talking to relatives and friends who are diabetics. What I became thrilled with was the ingenuity of Al Mann. The more I learned the more I respected Dr. Mann. This sort of experience is not new to me. When I was young I took courses and read books on computer programming and did some freelance work. The more I learned, the more I respected IBM (but not Microsoft). It’s the same here. Dr. Mann KNEW diabetes, and he new devices and medications and human physiology and he took what he knew and applied it and the result is Mannkind and Afrezza. Afrezza, the world’s only existing FDA approved inhalable human insulin. And it’s significant that it is “human” insulin and not an RAA like Exubera. That fact coupled with inhaled (and a whistle versus a bong) is the key to the fast in, fast out, action profile of Afrezza. And THAT action mimics the post-meal insulin spike of a healthy pancreas which is NOT what RAA insulins do. And the fact that RAA is even called “Rapid Acting” is something to pay attention to. This is a product differentiation, and the very reason the FDA should approve of the language “ultra-rapid” for Afrezza. Compared to RAA, Afrezza is ultra-rapid. How many videos of teenagers and adults describing the “life changing” result of that action does one need to see before they “get it”?
I’m still here, enjoying the excited chatter, and quiet lulls (but not the whiny nail-biting, 2nd guessing [although I indulge in that too] and soft-bashing) because of what Afrezza IS. And that is the best post-prandial insulin product in the world, period, bar none. And when that FINALLY gets realized, the chatter on this board will become very pleasant indeed, but I wonder too, will the board become the quietest it’s ever been and ever will be because of success?
|
|
|
Post by hellodolly on Mar 26, 2019 6:19:11 GMT -5
uvula makes an interesting point which is the correlation between this board’s activity and activity in the marketplace. Many of us hang on the barest shreds of information; a Tweet, Facebook exchanges, a post from a respected member of our community, an amateur (or not) blog or hit piece written on some Internet rag such as Seeking Alpha or Motley Fool, and let’s not forget, the weekly (or is that weakly?) prescription counts. Up until the flat-as-a-pancake Rx counts for the month of March, the general outlook had improved especially since the last quarter’s earnings report and the posting had become more buoyant. But the downward trend in the stock price (from “concerted” shorting?) at the end of last week capped by stalled TRx brought out the boo birds either real or incented as though something material had happened. One of the things I’ve decided I like about the TV DTC is it makes Afrezza “legit”. I’m confident folks will pounce on that. :-) The reason I assert this is we humans come to accept the things to which we have become accustomed, good or bad. The term used in advertising and marketing is mindshare. Afrezza is earning mindshare amongst prescribers, insurers, PWDs that were unaware of Afrezza (which is probably most of them), elected officials, regulators, distributors, pharmacists, investors. One can argue about the effectiveness but not the effect. I came here as an idiot investing in “inhalable insulin” because of course who the Hell WANTS to use needles on themselves? It just has to be a very small group. It’s weird that it is a group at all, but I won’t go there. I learned I didn’t know diddly squat about what I had invested in and that was very embarassing especially since I made a substantial investment, right after FDA approval. I couldn’t have timed it worse if I had tried, literally. And not being a saavy trader, I just accumulated more to at least try to benefit from dollar cost averaging, which is a great strategy that Sanofi contributed the most to. Then there was the 1:5 reverse split was also like a kick in the groin. And the very obvious dilution that was required that came afterward. Adam Fuerstein once called MNKD a “battleground stock”. I imagine something like the trench warfare in WWI with constant bombardment and the wide ranging battles causing a lot of civilians casualties too. Being here I also learned a lot about Afrezza and diabetes and from haunting Tudiabetes and reading DiabetesMine and talking to relatives and friends who are diabetics. What I became thrilled with was the ingenuity of Al Mann. The more I learned the more I respected Dr. Mann. This sort of experience is not new to me. When I was young I took courses and read books on computer programming and did some freelance work. The more I learned, the more I respected IBM (but not Microsoft). It’s the same here. Dr. Mann KNEW diabetes, and he new devices and medications and human physiology and he took what he knew and applied it and the result is Mannkind and Afrezza. Afrezza, the world’s only existing FDA approved inhalable human insulin. And it’s significant that it is “human” insulin and not an RAA like Exubera. That fact coupled with inhaled (and a whistle versus a bong) is the key to the fast in, fast out, action profile of Afrezza. And THAT action mimics the post-meal insulin spike of a healthy pancreas which is NOT what RAA insulins do. And the fact that RAA is even called “Rapid Acting” is something to pay attention to. This is a product differentiation, and the very reason the FDA should approve of the language “ultra-rapid” for Afrezza. Compared to RAA, Afrezza is ultra-rapid. How many videos of teenagers and adults describing the “life changing” result of that action does one need to see before they “get it”? I’m still here, enjoying the excited chatter, and quiet lulls (but not the whiny nail-biting, 2nd guessing [although I indulge in that too] and soft-bashing) because of what Afrezza IS. And that is the best post-prandial insulin product in the world, period, bar none. And when that FINALLY gets realized, the chatter on this board will become very pleasant indeed, but I wonder too, will the board become the quietest it’s ever been and ever will be because of success? Very few posts are 'must reads' but your posts are always in that category. Such a common sense, everyday "...the sun will rise and it will set..." post by you. You are very consistent and that is refreshing.
|
|